Last updated: 2026-09-06 21:42:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Vyome Holdings, Inc. (HIND) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.20, with a market capitalization of $15.30M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.75 to $9.56. This page covers its latest market performance, valuation, price trends and company information.
$15.30M | |
$2.15 | |
$16.00 | |
$1.75 | |
$2.23 | |
1.16K | |
-- | |
-- | |
$9.56 | |
$1.75 | |
-- | |
-- |
Vyome Holdings, Inc. (HIND) last closed at $2.23 as of 2026-09-04 23:31:00, unchanged from the previous close of $2.23.
During the latest regular trading session, HIND traded between $1.75 and $16.00, with a volume of 1.16K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Vyome Holdings, Inc. (HIND) moved from $2.16 to $2.20, representing a gain of 1.85% ($0.04).
The stock traded between $2.16 and $2.21 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 5.54 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 5.8%
HIND is currently trading at $2.20, placing it 5.8% of the way from its 52-week low of $1.75 to its 52-week high of $9.56. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 18 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vyome Holdings, Inc. (HIND) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.